Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain Authors: Ignacio Salamanca de la Cueva, María González López, Reyes Roldán López, Beatriz Relinque Macías, Sergio Ocaña Jaramillo, Manuel Baca Cots, Javier Álvarez Aldeán, Benito Amil Pérez Published: 2026 ABSTRACT ABSTRACTPreterm infants are at higher risk of mortality, disabilities, and infections. Hexavalent DTaP-IPV-HB-Hib vaccines against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b are standards of care in pediatric immunization. Evidence on the use of these vaccines in preterm infants remains limited, particularly in extreme preterms. This open-label, multicenter, non-randomized phase IV trial conducted in Spain evaluated the immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib vaccine in preterm infants (stratified by gestational age: 24–27, 28–30, 31–33, 34–36 weeks). Immunogenicity was described using seroprotection/vaccine response (VR) rates. Safety was described using solicited and unsolicited adverse events (AEs). A total of 143 infants received at least one vaccination (22 born at 24–27 weeks of gestation, 29 at 28–30 weeks, 38 at 31–33 weeks, and 54 at 34–36 weeks), 135 received three doses, and 132 completed the study. Post-dose 3 seroprotection rates were 100% against diphtheria (≥0.1 UI/mL), tetanus (≥0.1 UI/mL), and polio type 1/2/3 (≥8/dil), 94.5% against hepatitis B (≥10 mIU/mL), and 92.3% against polyribosylribitol phosphate (≥1 µg/mL). VR rates against pertussis toxoid and filamentous hemagglutinin were 94.1% and 76.5%, respectively. Within 7 days post-vaccination, 51.0% of participants experienced solicited AE related to vaccination, 0.7% reporting Grade 3 AEs. Within 30 days post-vaccination, 9.8% of infants had unsolicited related AEs (none of Grade 3). No serious AEs considered related were reported. This study demonstrated that a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine is immunogenic and well tolerated in preterm infants.Trial registration: EudraCT Number: 2018-004581-34.KEYWORDS: Hexavalent vaccine, preterm infants, extremely preterm infants, immunogenicity, reactogenicity, safety, phase IV trial, 2+1 immunization schedule Introduction Multivalent pediatric combination vaccines play a vital role in maintaining protection against multiple infectious diseases during early childhood.1,2 These vaccines reduce the number of required injections, simplify operational procedures, and improve compliance with increasingly complex vaccination schedules, contributing to comprehensive disease prevention strategies.2,3 Hexavalent DTaP-IPV-HB-Hib vaccines against diphtheria (D), tetanus (T), pertussis (whooping cough), poliomyelitis, hepatitis B (HB), and Haemophilus influenzae type b infections have been included in many pediatric immunization programs in Europe and beyond, including high-risk children vulnerable to vaccine-preventable diseases, such as preterm infants.2,4–6 According to the WHO definition, preterm birth is defined as delivery before 37 completed weeks of gestation.7 Prematurity is stratified into four clinically relevant gestational-age categories: extremely preterm (<28 weeks of gestation), very preterm (28 to 31 weeks and 6 days), moderate preterm (32 to 33 weeks and 6 days), and late preterm (34 to 36 weeks and 6 days).7,8 Globally, around 10% of infants are born prematurely.9 Late and moderate preterm infants account for approximately 85% of all preterm births, whereas very preterm infants represent about 10% and extremely preterm infants 5%.9 In Spain, an overall rate of preterm birth of 8.3% was reported in 2018, with late preterm infants comprising 71.8% of them.10 Preterm birth complications represent the leading cause of mortality among children under 5 years of age and a major contributor to morbidity and long-term disabilities.7,11,12 In addition, preterm infants are more susceptible to life-threatening infections, including vaccine-preventable diseases, due to their immature immune system and reduced immunocompetence.6,13,14 Indeed, functional immunologic immaturities in preterm infants affect vaccine responses, as some studies have suggested that antibody responses to initial doses may be lower in preterm infants compared to term infants, although protective antibody concentrations are often reached.6,15 Moreover, preterm infants are at increased risk of nonspecific adverse events (AEs) following injections, and, thus, hexavalent vaccines are particularly important to ensure their full protection while reducing the risk of these AEs by reducing the number of injections.2 While vaccination of preterm infants is recommended as per chronological age, it is frequently delayed, likely due to limited knowledge about vaccine safety and effectiveness in this population.6,16 This delay exposes these infants to a serious risk of disease. Therefore, timely immunization of preterm infants is essential to ensure optimal protection. Although the safety, immunogenicity, and effectiveness of the hexavalent vaccines in preterm infants have been shown in some studies, supporting the use of DTaP-IPV-HB-Hib in preterm infants, data remain limited, particularly for those born extremely preterm and for the 2 + 1 schedule, which is currently recommended and standard of care in several European Union member states, including Spain, regardless of gestational age.2,16–19 Thus, this observational study was conceived to provide real-world evidence on the well-established 2 + 1 vaccination schedule in preterm infants. For this purpose, we aimed to describe the immunogenicity and safety of the hexavalent DTaP-IPV-HB-Hib vaccine under the 2 + 1 schedule at 2, 4, and 11 months of age in preterm infants, including those born extremely preterm. Materials and methods Study design and participants This study was an open-label, multicenter, non-randomized phase IV trial conducted in 5 hospitals in Spain to evaluate the immunogenicity and safety of the hexavalent DTaP-IPV-HB-Hib vaccine in preterm infants (EudraCT Number: 2018-004581-34). Eligible participants were consecutively enrolled and consisted of healthy preterm infants born between 24 and 36 weeks of gestation. Infants were stratified by gestational age (24–27, 28–30, 31–33, and 34–36 weeks). The main exclusion criteria were the use of any investigational product within 30 days before the first dose of the study vaccine, prolonged administration of immunosuppressive therapy, participation in another clinical trial, immunodeficiency, major congenital disabilities, serious chronic diseases, and a history of D, T, pertussis, HB, polio, and Haemophilus influenzae type b vaccination or disease. Participants received a vaccination schedule consisting of three doses (2 + 1 schedule) of the hexavalent vaccine administered intramuscularly at 2, 4, and 11 months of age. Study follow-up time extended to 30 days following receipt of dose 3. Hexavalent vaccine is a fully liquid D, T, pertussis (acellular, component), HB (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (DTaP-IPV-HB-Hib: Hexyon®, Sanofi, France). The commercial DTaP-IPV-HB-Hib vaccine was administered as part of the Spanish national vaccination program in primary care settings. Different batches of the vaccine were used. All data were obtained from infants’ medical records. All participants were managed in accordance with routine clinical practice. Thus, the administration of all concomitant pediatric vaccines (e.g., pneumococcal conjugate vaccine, meningococcal vaccine, rotavirus vaccine, and influenza vaccine) authorized in Spain was permitted.18,20 As pertussis vaccination in pregnancy is part of the national immunization program in Spain, infants included in the study were either born to vaccinated women or not, this information was collected. All women vaccinated against pertussis during pregnancy received a T, D, pertussis (Tdap) vaccine. The present study was approved by the Ethics Committee of “Comité Coordinador de la Investigación Biomédica de Andalucía” in Spain on the 20th of February 2019. The study adhered to ethical principles consistent with the Declaration of Helsinki (1964 and its subsequent amendments), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice (ICH/GCP), and applicable legislation. Infants were included in the study once informed consent was obtained from the parent(s)/legal representative(s). Study endpoints The primary objective of the study was to describe the immunogenicity of a 2 + 1 schedule of the hexavalent vaccine in preterm infants. For this purpose, seroprotection/seroconversion and vaccine response (VR) rates 1 month post-dose 3 (booster) were assessed. Blood samples were collected at three time points: immediately before dose 1 (pre-vaccination level), on the day of dose 3 before vaccination (pre-dose 3), and 30 days after dose 3 (post-dose 3). All serologic analyses were performed using validated assays at Sanofi’s Global Clinical Immunology (GCI) laboratory (Swiftwater, PA, USA) as previously described; testing was conducted blinded to gestational‑age strata.21 The following antibodies were measured: anti-D toxin, anti-T toxin, anti-pertussis toxoid (PT), anti-filamentous hemagglutinin pertussis antigen (FHA), anti-poliovirus serotype 1 (Mahoney; antigen of the poliovirus, serotype 1), type 2 (MEF-1; antigen of the poliovirus, serotype 1), and type 3 (Saukett; antigen of the poliovirus, serotype 1), anti-hepatitis B (anti-HB), and anti-polyribosylribitol phosphate Haemophilus influenzae antigen (anti-PRP). The seroprotection/seroconversion thresholds used during the analysis are shown in Supplemental Table 1. Seroprotection rates were assessed for anti-D, anti-T, anti-polio types 1, 2, and 3, anti-HB, and anti-PRP, and seroconversion rates for anti-PT and anti-FHA. The study’s secondary objectives included describing the reactogenicity of the DTaP-IPV-HB-Hib vaccine, focusing on solicited AEs related to vaccination within 7 days after each dose. Solicited AEs consisted of injection-site AEs (tenderness or pain, redness, and swelling) and systemic AEs (fever, irritability, abnormal crying, loss of appetite, vomiting, and somnolence). Unsolicited AEs within 30 days after vaccination, serious AEs (SAEs), and AEs of special interest (AESIs) during the entire study period were evaluated. AEs were reported using Medical Dictionary for Regulatory Activities (MedDRA) coding and assessed regarding severity and relationship to the study vaccines. Additionally, demographic and anthropometric data, medical history (using MedDRA coding), prior maternal vaccination, and concomitant vaccination of the preterm infants were described. Statistical analysis All analyses, including immunogenicity and safety analyses, were performed in all participants who received at least one dose of the study vaccine. For immunogenicity analysis, the percentage of infants who presented seroprotection/seroconversion was expressed with exact 95% confidence intervals (CI) at pre-dose 3 and post-dose 3. For pertussis, the proportion of preterm infants with VR, along with the exact 95% CI, was calculated post-dose 3. VR was defined as an antibody concentration of ≥8 ELISA units (EU)/mL post-dose 3 if the antibody concentration pre-vaccination was <8 EU/mL, or as an increase in antibody concentration from pre-vaccination to post-dose 3 if the antibody concentration before dose 1 was ≥8 EU/mL. Reactogenicity and unsolicited AE data were described as the proportion of study infants reporting AEs expressed with exact 95% CI. Demographic and anthropometric characteristics and clinical history were summarized using descriptive statistical analysis. Quantitative variables were described using measures of central tendency and dispersion (including mean and standard deviation [SD]). Qualitative variables were expressed as absolute and relative frequencies. All analyses were conducted for the whole study population and by strata of gestational age at birth (24–27, 28–30, 31–33, and 34–36 weeks). For each category/variable, the number of missing data was provided; no imputation of missing data was done. A sample size of 140 infants (21 infants born at 24–27 weeks of gestation, 28 at 28–30 weeks, 35 at 31–33 weeks, and 56 at 34–36 weeks) was estimated to provide sufficient power to examine the primary study objective. The assumptions used to calculate the sample size were obtained from a previous study where 92.5% of the 94 preterm infants enrolled to receive 3 doses of a hexavalent DTPa-HBV-IPV/Hib vaccine at 2, 4, and 6 months reached levels of anti-PRP titers ≥0.15 μg/mL.22 Assuming a CI with absolute precision of ±4.5%, the sample size was N = 132 infants. To compensate for potential loss to follow-up, the target sample size was increased to 140 preterm infants. Data were analyzed using SAS version 9.4, under the Enterprise Guide Interface v8.3 (SAS Institute Inc., Cary, NC, USA). Results Participants Between July 2019 and May 2022, a total of 152 preterm infants were included in this study. The participant disposition through the study is shown in Figure 1. After enrollment, nine participants were not vaccinated and, thus, excluded. After dose 1, three participants were lost to follow-up. After doses 2 and 3, five and three participants, respectively, withdrew from the study. Overall, 143 infants received at least one vaccination, 140 received two doses, 135 received three doses, and 132 completed the study. Thus, the recruitment objective of a total of 140 preterm infants was achieved. Participant disposition. *Weeks of gestation. Among the 143 participants who received at least one dose, 22 (15.4%) infants were born at 24–27 weeks of gestation, 29 (20.3%) at 28–30 weeks, 38 (26.6%) at 31–33 weeks, and 54 (37.8%) at 34–36 weeks. Baseline characteristics of the study populations We present stratified results by infant subgroups categorized by weeks of gestation (Table 1). For the overall population, the mean (SD) age at the time of dose 1 was 65.6 (8.5) days. For infants born at 24–27, 28–30, 31–33, and 34–36 weeks of gestation, the mean (SD) age at the time of dose 1 was 73.9 (12.5), 65.2 (9.4), 63.9 (7.0), and 63.6 (3.9) days, respectively. Table 1.Baseline characteristics of participants.Variable24–27 weeks(N = 22)28–30 weeks(N = 29)31–33 weeks(N = 38)34–36 weeks(N = 54)Overall(N = 143)Demographic Mean age at dose 1, days (SD)73.9 (12.5)65.2 (9.4)63.9 (7.0)63.6 (3.9)65.6 (8.5)Female, n (%)14 (63.6)13 (44.8)15 (39.5)28 (51.9)70 (49.0)Anthropometric data Mean weight, kg (SD) At screening visit (between birth and dose 1 [2 MoA])2.0 (0.4)2.2 (0.6)2.4 (0.7)3.1 (1.1)2.6 (0.9) At dose 1 (2 MoA)2.0 (0.3)2.9 (0.6)a3.6 (0.7)b4.4 (0.7)a3.5 (1.1)c At dose 3 (11 MoA)7.3 (1.1)8.8 (1.5)d8.3 (1.3)d8.8 (1.0)a8.4 (1.3)eMedical history, n (%)f Infants with at least one diagnosis22 (100.0)29 (100.0)36 (94.7)48 (88.9)135 (94.4) Respiratory, thoracic, and mediastinal disorders22 (100.0)29 (100.0)26 (68.4)19 (35.2)96 (67.1) Hepatobiliary disorders12 (54.5)14 (48.3)13 (34.2)27 (50.0)66 (46.2) Infections and infestations18 (81.8)8 (27.6)7 (18.4)6 (11.1)39 (27.3)Prior vaccination of the mother, n (%) Vaccination during pregnancy10 (66.7)g13 (65.0)h30 (93.8)i47 (94.0)e100 (85.5)j Tetanus, diphtheria, acellular pertussis1 (10.0)9 (69.2)28 (93.3)46 (97.9)84 (84.0) Flu vaccine10 (100.0)12 (92.3)18 (60.0)16 (34.0)56 (56.0)Concomitant vaccination of the preterm infant, n (%) Dose 122 (100.0)26 (89.7)38 (100.0)52 (96.3)138 (96.5) Pneumococcal Conjugate Vaccine22 (100.0)26 (89.7)38 (100.0)52 (96.3)138 (96.5) Rotavirus Vaccine4 (18.2)9 (31.0)19 (50.0)30 (55.6)62 (43.4) Meningococcal B0 (0.0)1 (3.4)0 (0.0)2 (3.7)3 (2.1)Dose 222 (100.0)28 (96.6)37 (97.4)51 (94.4)138 (96.5) Pneumococcal Conjugate Vaccine21 (95.5)28 (96.6)36 (94.7)50 (92.6)135 (94.4) Meningococcal C22 (100.0)25 (86.2)34 (89.5)48 (88.9)129 (90.2) Rotavirus Vaccine6 (27.3)6 (20.7)14 (36.8)25 (46.3)51 (35.7) Meningococcal ACWY0 (0.0)3 (10.3)1 (2.6)0 (0.0)4 (2.8) Meningococcal B0 (0.0)0 (0.0)1 (2.6)3 (5.6)4 (2.8)Dose 320 (90.9)23 (79.3)33 (86.8)44 (81.5)120 (83.9) Pneumococcal Conjugate Vaccine19 (86.4)23 (79.3)33 (86.8)44 (81.5)119 (83.2) Flu2 (9.1)0 (0.0)4 (10.5)2 (3.7)8 (5.6) Measles, mumps, and rubella vaccine2 (9.1)0 (0.0)0 (0.0)1 (1.9)3 (2.1) Meningococcal ACWY1 (4.5)1 (3.4)0 (0.0)1 (1.9)3 (2.1)aMissing data n = 2. bMissing data n = 5. cMissing data n = 9. dMissing data n = 1. eMissing data n = 4. fThe three most frequent SOC are shown. Each infant counts only once in each category. Each infant can count toward several categories. Codification using MedDRA v27.0. gMissing data n = 7. hMissing data n = 9. iMissing data n = 6. jMissing data n = 26. MoA: Months of age; SD: Standard deviation; SOC: System organ class. Baseline characteristics of participants. aMissing data n = 2. bMissing data n = 5. cMissing data n = 9. dMissing data n = 1. eMissing data n = 4. fThe three most frequent SOC are shown. Each infant counts only once in each category. Each infant can count toward several categories. Codification using MedDRA v27.0. gMissing data n = 7. hMissing data n = 9. iMissing data n = 6. jMissing data n = 26. MoA: Months of age; SD: Standard deviation; SOC: System organ class. The mean (SD) weight at the time of dose 1 was 2.0 (0.3) kg for infants born at 24–27 weeks of gestation, 2.9 (0.6) kg for those born at 28–30 weeks, 3.6 (0.7) kg for those born at 31–33 weeks, and 4.4 (0.7) kg for those born at 34–36 weeks. At the time of dose 3, the mean (SD) weight was 7.3 (1.1), 8.8 (1.5), 8.3 (1.3), and 8.8 (1.0) kg, respectively. All (100%) of participants born at 24–27 and 28–30 weeks of gestation, 94.7% of those born at 31–33 weeks, and 88.9% of those born at 34–36 weeks had been diagnosed with a condition since birth, with respiratory, thoracic, mediastinal, or hepatobiliary disorders and infections and infestations being the most frequent. Among preterm infants with available data regarding vaccination in pregnancy, most of them were born to vaccinated women against Tdap or flu: 66.7% of infants born at 24–27 weeks of gestation, 65.0% of those born at 28–30 weeks, 93.8% at 31–33 weeks, and 94.0% at 34–36 weeks. Among these infants, 10% of those born at 24–27 weeks of gestation, 69.2% at 28–30 weeks, 93.3% at 31–33 weeks, and 97.9% at 34–36 weeks had mothers vaccinated against Tdap during pregnancy. The mean (SD) time from Tdap vaccination of the mother during pregnancy to the birth of the preterm infant was 4.0 (-) days for the infant born at 24–27 weeks of gestation, 34.4 (54.5) days for those born at 28–30 weeks, 34.6 (35.9) days for those born at 31–33 weeks, and 49.7 (32.4) days for those born at 34–36 weeks. A hundred and thirty-eight (96.5%) infants received concomitant pneumococcal conjugate vaccine at dose 1, 135 (94.4%) at dose 2, and 119 (83.2%) at dose 3; 62 (43.4%) infants received concomitant rotavirus vaccine at dose 1 and 51 (35.7%) at dose 2; and 129 (90.2%) infants received concomitant meningococcal C vaccine at dose 2. Immunogenicity of a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine The immunogenicity of a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine in preterm infants was measured as the seroprotection/seroconversion and VR rates after dose 3. Post-dose 3 seroprotection/seroconversion rates in preterm infants are shown in Figure 2 and Supplemental Table 2. Pre-dose 3 seroprotection/seroconversion rates are also shown. Pre- and post-dose 3 seroprotection/seroconversion. The percentage and 95% CI are shown. Seroprotection (for anti-D, anti-T, anti-polio 1, 2, and 3, anti-HB, and anti-PRP) and seroconversion (for anti-PT and anti-FHA) rates are shown. 24–27 weeks (N = 22); 28–30 weeks (N = 29); 31–33 weeks (N = 38); 34–36 weeks gestational age (N = 54); all (N = 143). CI: Confidence interval; D: Diphtheria toxoid antigen; dil: Dilutions; EU: ELISA units; FHA: Filamentous hemagglutinin antigen; HB: Hepatitis B; IU: International units; PRP: Polyribosylribitol phosphate; PT: Pertussis toxoid antigen; SP: Seroprotection; T: Tetanus toxoid antigen. For the overall study population, post-dose 3 seroprotection rates were 100.0% against D, T, and polio types 1, 2, and 3; 94.5% against HB, and 92.3% against PRP. Regarding seroconversion rates against pertussis antigens, 99.2% and 100% of infants developed antibodies ≥8 EU/mL against PT and FHA antigens, respectively. All subgroups of preterm infants showed similar post-dose 3 seroprotection/seroconversion rates against the different antigens, except for a slightly lower rate against PRP in extremely preterm infants (81.0%). Overall VR rates against pertussis antigens were 94.1% and 76.5%, respectively (Figure 3, Supplemental Table 3, and Supplemental Table 4). Post-dose 3 VR against PT ranged from 100.0% to 84.8% across strata, with the lowest value observed in those born at 34–36 weeks. Post-dose 3 VR against FHA ranged from 100.0% to 58.7% for the different strata, with a tendency for a decrease with gestational age. This observation may be related to the higher proportion of infants born to Tdap-vaccinated women in late to moderate preterm infants and, thus, a higher pre-vaccination level in these groups (Table 1 and Supplemental Table 4). Post-dose 3 vaccine response against pertussis antigens. Vaccine response was defined as an antibody concentration of ≥8 EU/mL post-dose 3 if the antibody concentration pre-vaccination was <8 EU/mL, or as an increase in antibody concentration from pre-vaccination to post-dose 3 if the antibody concentration before dose 1 was ≥8 EU/mL. The percentage and 95% CI are shown. 24–27 weeks (N = 22); 28–30 weeks (N = 29); 31–33 weeks (N = 38); 34–36 weeks gestational age (N = 54); all (N = 143). CI: Confidence interval; EU: ELISA units; FHA: Filamentous hemagglutinin antigen; PT: Pertussis toxoid antigen. Reactogenicity The solicited AEs related to vaccination are shown in Figure 4 and Supplemental Table 5. Overall, 73 (51.0%) infants experienced at least one solicited AEs related to vaccination, including 16 (11.2%) who reported injection site AEs and 69 (48.3%) who reported systemic AEs. The injection site AEs were swelling (n = 11; 7.7%) and pain (n = 7; 4.9%). The most frequently reported systemic AEs were pyrexia (n = 64; 44.8%), irritability (n = 8; 5.6%), and vomiting (n = 7; 4.9%). One (0.7%) participant, born at 31–33 weeks of gestation, reported a Grade 3 solicited AE, identified as pyrexia. Reactogenicity. Reactogenicity within 7 days after any of the three vaccinations. The percentage and 95% CI are shown. Solicited injection site (A) or systemic adverse event (B) within 7 days after vaccination. Safety (unsolicited AEs) The unsolicited AEs are shown in Table 2. Overall, 64 (44.8%) preterm infants experienced unsolicited AEs. Most reported unsolicited AEs (n = 61; 42.7%) were of Grade 1 severity, while only 6 participants (4.2%) reported Grade 2 unsolicited AEs, and no Grade 3 unsolicited AEs were reported. Unsolicited AEs reported as related were experienced by 14 (9.8%) infants, two (9.1%) infants born at 24–27 weeks of gestation, two (6.9%) born at 28–30 weeks, three (7.9%) born at 31–33 weeks, and seven (13.0%) born at 34–36 weeks, including four (2.8%) infants reporting temperature regulation disorder, and two (1.4%) peripheral swelling and vaccination site pain. SAEs, none of them related to the vaccine, were experienced by 15 (10.5%) infants: four (18.2%) infants born at 24–27 weeks of gestation, five (17.2%) born at 28–30 weeks, four (10.5%) born at 31–33 weeks, and two (3.7%) born at 34–36 weeks. AESIs were observed in two (1.4%) infants, both born at 28–30 weeks of gestation and not related to the vaccine: one with apnea, and another with apnea and cyanosis. No death occurred. Table 2.Unsolicited AEs.Event, N (% [95% CI])24–27 weeks(N = 22)28–30 weeks(N = 29)31–33 weeks(N = 38)34–36 weeks(N = 54)Overall(N = 143)Infants with at least oneUnsolicited AE8 (36.4 [17.2; 59.3])10 (34.5 [17.9; 54.3])13 (34.2 [19.6; 51.4])33 (61.1 [46.9; 74.1])64 (44.8 [36.4; 53.3])Related unsolicited AE2 (9.1 [1.1; 29.2])2 (6.9 [0.8; 22.8])3 (7.9 [1.7; 21.4])7 (13.0 [5.4; 24.9])14 (9.8 [5.5; 15.9])SAE4 (18.2 [5.2; 40.3])5 (17.2 [5.8; 35.8])4 (10.5 [2.9; 24.8])2 (3.7 [0.5; 12.7])15 (10.5 [6.0; 16.7])AESI0 (0.0 [–])2 (6.9 [0.8; 22.8])0 (0.0 [–])0 (0.0 [–])2 (1.4 [0.2; 5.0])Unsolicited AEs within 30 days after any of the three vaccinations. AE: Adverse event; AESI: Adverse event special interest; SAE: Severe adverse event. Unsolicited AEs. Unsolicited AEs within 30 days after any of the three vaccinations. AE: Adverse event; AESI: Adverse event special interest; SAE: Severe adverse event. Discussion This phase IV trial described for the first time the immunogenicity and safety of the hexavalent DTaP-IPV-HB-Hib vaccine under the 2 + 1 schedule in a Spanish cohort of preterm infants, including extremely preterm infants. Stratification by gestational age ensured a representative distribution of preterm infants, thereby enhancing the clinical relevance of the study’s findings and facilitating comparability with previous vaccine evaluations in preterm populations. In addition, extremely preterm infants were deliberately over-sampled to strengthen the robustness of the findings estimates in this high‑risk subgroup, which is frequently underrepresented in clinical studies.16 Nevertheless, findings on the gestational-age subgroup analysis remain limited by the small sample size within each subgroup and should be interpreted with caution. The primary objective was to describe the immunogenicity of a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine in preterm infants. The post-booster seroprotection for the overall study population were 100.0% against D, T, and polio types 1, 2, and 3; 94.5% against HB; and 92.3% against PRP. Seroconversion rates against pertussis antigens were 99.2% and 100% for PT and FHA, respectively, and VR rates were 94.1% and 76.5%, respectively. These very positive results are in line with previous evidence on the hexavalent vaccine in term and preterm infants under both 2 + 1 and 3 + 1 schedules.2 For instance, a phase III, randomized, active-controlled trial evaluated the DTaP-IPV-HB-Hib vaccine in a 2 + 1 schedule (at 3, 5, and 11 to 12 months of age) in full-term infants (N = 275) and showed similar seroprotection, seroconversion, and VR rates.23 A prospective, observational study showed comparable immunogenicity induced by the DTaP-IPV-HB-Hib vaccine in a 3 + 1 schedule (at 2, 3, and 4 months of age, with a booster at 13 months) in both preterm infants (N = 105) and term infants (N = 127).21 In addition, these findings are consistent with those reported for the hexavalent DTPa-HBV-IPV/Hib vaccine in preterm infants in several studies and countries administered in a 3 + 1 schedule.16 Furthermore, our post-booster results in preterm infants are similar to those shown in term infants, regardless of the schedule, as presented in the Summary of Product Characteristics (SmPC) of the vaccine.19 Despite the overall comparable post‑booster immunogenicity with previous evidence, pre-booster concentrations of anti-PRP, anti-HBs, and anti-polio type 3 antibodies appear to be slightly lower following the 2-dose primary vaccination schedule in preterm infants from our study compared with those reported for the overall infant population 2 or for the three-dose primary series in preterm infants.21,22 This observation could suggest a potential benefit of a 3-dose regimen in preterm infants. Nevertheless, real‑world evidence to date has not indicated any reduction in the 2 + 1 scheme’s vaccine effectiveness or safety before booster administration in settings with high vaccination coverage.24,25 Furthermore, to our knowledge, no healthcare system that has implemented a 2 + 1 schedule has subsequently reverted to a 3 + 1 schedule. A distinctive aspect of our study, compared with previous research on hexavalent vaccines in preterm infants, is the presentation of highly detailed, stratified data by gestational age. Notably, in our study seroprotection/seroconversion rates remained consistent as gestational age decreased, except for slightly lower values of anti-PRP in extremely preterm infants (81% with post-dose 3 of anti-PRP ≥1 µg/mL). Overall, these findings suggest a high immunogenicity of the 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine against all antigens across strata of preterm infants, supporting the established routine vaccination based on chronological age, independent of gestational age. However, additional evidence would be valuable to further confirm these findings. Pertussis outbreaks and infections have been particularly high since 2023.26–28 Infants aged <1 year have historically had the highest incidence and morbidity-mortality associated with pertussis; therefore, a timely and complete immunization is recommended, regardless of the vaccination schedule.28 Our findings demonstrated that the 2 + 1 vaccination scheme induces high immunogenicity against pertussis in preterm infants. Thus, other factors might be associated with this epidemiological situation, including suboptimal coverage and an increase in infections among teens and adolescents. For instance, in Spain, children aged 10–14 y had the highest incidence of pertussis infections in early 2024.28 Tdap vaccination during pregnancy, preferably during weeks 27 or 28, is another practice recommended and implemented in several countries, including Spain.18 Indeed, in our study, despite a high number of missing values, more than 90% of moderate and late preterm infants with available data were born to Tdap-vaccinated women, while around 70% of very preterm infants and only one extremely preterm infant were born to Tdap-vaccinated women. Despite these differences between subgroups of preterm infants, post-dose 3 seroprotection rates against D and T were similar across subgroups. In addition, anti-PT and anti-FHA antibodies were ≥8 EU/mL in at least 98% of preterm infants across all strata. Interestingly, VR rates against PT and FHA tend to decline as gestational age increases, likely reflecting the documented impact of Tdap vaccination in pregnancy on the infant’s immune response to their primary vaccination, which increases with gestational age. Detailed analysis stratified by maternal vaccination status could have been of interest; however, this observational phase IV study was conceived to provide real-world evidence on a well-established vaccination schedule implemented in our region, where infants are vaccinated regardless of maternal vaccination status. Overall, immune responses remained robust, and, as existing evidence indicates that the immunological interference of Tdap vaccination in pregnancy does not affect clinical protection afforded by primary immunization, these findings support the use of DTaP-IPV-HB-Hib vaccine in preterm infants born to Tdap-vaccinated or Tdap-unvaccinated women, as previously suggested.21,29,30 Future studies specifically designed and powered to evaluate the impact of maternal Tdap vaccination on infant immunogenicity would be of interest. The secondary objectives of the study included evaluating the reactogenicity of the DTaP-IPV-HB-Hib vaccine. After DTaP-IPV-HB-Hib vaccination, the most frequent AEs were swelling (7.7%) and pain (4.9%) at the injection site, and pyrexia (44.8%), irritability (5.6%), and vomiting (4.9%) as systemic AEs, all of them previously reported as very common (≥1/10) adverse reactions in children vaccinated with the DTaP-IPV-HB-Hib vaccine.19 Notably, only one participant, born at 31–33 weeks of gestation, reported a Grade 3 solicited AE, identified as pyrexia. Overall, approximately 48% of infants reported systemic AEs, consistent with the established safety profile of hexavalent vaccines, for which clinical trials have reported solicited systemic reaction rates above 90%.2 The findings from our prospective clinical study are also in line with those shown in a post-marketing retrospective surveillance study conducted in Italy in 339 preterm infants, including 294 participants born at week 32–38 of gestation, 44 born at week 28–32, and one born before week 28, who received the DTaP-IPV-HB-Hib vaccine in 2017.31 In addition, our results are consistent with those reported for the hexavalent DTPa-HBV-IPV/Hib vaccine in both preterm and term infants in several prospective and retrospective studies.16 Regarding unsolicited AEs, less than 10% of participants experienced related AEs; none were Grade 3 or SAEs, in line with previous reports that found no related SAEs in preterm infants.21,31 AESIs, not related to the study vaccine, were found in two infants born at 28–30 weeks of gestation, one of them with apnea, and another with apnea leading to cyanosis. Of interest, the reported AEs were consistent across all gestational age groups. Overall, the 2 + 1 vaccination scheme using the DTaP-IPV-HB-Hib vaccine, co-administered with other infant routine vaccines (pneumococcal conjugate, rotavirus, meningococcal C vaccines), was well tolerated across all strata of preterm infants, including those who were extremely preterm. Altogether, these findings support the use of the 2 + 1 vaccination schedule of the DTaP-IPV-HB-Hib vaccine, co-administered with other infant routine vaccines, as standard clinical practice for all infants, including those born preterm, as it shows comparable outcomes compared to alternative schedules. Certain limitations of this study should be acknowledged, such as the absence of a parallel control arm of term infants. However, considering that the 2 + 1 vaccination schedule of the DTaP-IPV-HB-Hib vaccine is already well established and has been previously evaluated in term infants in another study, the lack of a control arm may not represent a major limitation.18,20,23 Additionally, the absence of post‑primary immunogenicity data prevents evaluation of effectiveness following primary vaccination. However, additional blood draws were avoided to limit invasive procedures in premature infants, given that this was a phase IV study of an already‑established vaccination schedule. In addition, pre‑booster (pre‑dose 3) immunogenicity assessment still provides meaningful information, as it reflects the sustained immunogenicity elicited by the primary vaccination. This study has several important strengths. Its design aligns with the 2 + 1 vaccination schedule, consistent with standard clinical practice and national recommendations for all infants in countries such as Spain.2,19 Since routine vaccination of preterm infants is conducted in primary care settings in Spain, as in this study, the findings are readily translatable to clinical practice. Moreover, stratifying by gestational age ensured a balanced representation of preterm infants, including those who are extremely preterm, although these findings should be interpreted with caution, given the limited sample size within each subgroup. In addition, all serologic testing was performed blinded to gestational‑age strata, using validated assays, and safety data were captured with identical solicited and unsolicited AEs used in earlier trials.19 These strengths increase the clinical relevance of the findings, maximize their external validity, and facilitate comparability with previous vaccine studies in preterm and term populations. In conclusion, findings from this trial conducted in preterm infants in Spain described the high immunogenicity and good tolerability of the hexavalent DTaP-IPV-HB-Hib vaccine, administered in a 2 + 1 schedule and co-administered with other infant routine vaccines (pneumococcal conjugate, rotavirus, meningococcal C vaccines), supporting its use as primary and booster vaccination in preterm infants. Supplementary Material supplementary files.docx Acknowledgments Evidenze Health España, S.L.U. (Clinical Research Unit) provided medical writing support during the preparation of this manuscript. The authors would also like to thank all the investigators at the participating sites, as well as María Ángeles Clemente Maya (from Sanofi), for the support in coordinating the procedures of the independent study sponsored by Sanofi. Additionally, the authors thank Céline Petit and Armelle Marais (both from Sanofi) for coordinating sample shipments and testing at GCI, and Florence Boisnard (from Sanofi) for her valuable assistance in revising the output of the study. During the preparation of this work, the authors used Copilot (Microsoft) to verify grammar and improve the clarity of the text. After using this tool, the authors carefully reviewed, edited, and approved the content as needed, and take full responsibility for the content of the published article. Biographies Ignacio Salamanca de la Cueva: Medical Coordinator of the Research Unit at Grupo IHP, specialized in pediatric research and vaccine development across all population groups and research phases, with a strong dedication to training, scientific dissemination, and vaccination advocacy. Practicing physician at Grupo IHP Pediatría (www.ihppediatria.com), focused on pediatric clinical care. Member of the Advisory Committee for the Strategic Vaccination Plan of Andalusia and Board Member of the Vaccine Advisory Committee of the Spanish Association of Pediatrics (Asociación Española de Pediatría). María González López: Pediatrician specialized in neonatology in a tertiary-level neonatology ward, with special focus on research on neonatal infectious diseases. Contribution to medical students’ training in the University of Málaga. Reyes Roldán López: Pediatrician specialized in neonatology in a tertiary-level neonatology ward. Contribution to medical students’ training in the University of Málaga. Beatriz Relinque Macías: Consultant pediatrician specialized in neonatology at the Group IHP (Instituto Hispalense de Pediatría). Clinical and research interests focus on neonatal care and infant health. Sergio Ocaña Jaramillo: Specialist in Pediatrics at Hospital Universitario Costa del Sol and specialized in Neonatology and Pediatric Pulmonology. Manuel Baca Cots: Head of the Department of Pediatrics and Neonatology at Quirónsalud Málaga Hospital, Lead of the Uncibay Pediatric Group, and clinical trial investigator in vaccine development. Javier Álvarez Aldeán: Pediatrician in Málaga (Spain). Member of the Advisory Committee for the Strategic Vaccination Plan of Andalusia and Board Member of the Vaccine Advisory Committee of the Spanish Association of Pediatrics (Asociación Española de Pediatría). Benito Amil Pérez: Consultant pediatrician specialized in pediatric clinical care and pediatric nephrology at the Group IHP (Instituto Hispalense de Pediatría). Funding Statement This study was conducted by the Fundación IHP – Grupo IHP (Instituto Hispalense de Pediatría) and funded by Sanofi. Disclosure statement This study was conducted by the Fundación IHP – Grupo IHP (Instituto Hispalense de Pediatría) and funded by Sanofi. Participating institutions received financial support for their participation. Ignacio Salamanca de la Cueva has collaborated in scientific training activities subsidized by GlaxoSmithKline, MSD, Pfizer, Sanofi, Seqirus, Novavax, and Moderna; as an investigator in clinical trials of vaccines from Ablynx, Abbot, Almirall, Allergan, AstraZeneca, Biomedal, GlaxoSmithKline, Janssen, Lilly, Medimmune, Merck, Moderna, MSD, Nestlé, Novavax, Novartis, Nutricia, Pfizer, Roche, Regeneron, Sanofi, Seqirus, and Wyeth; and as a consultant on the Advisory Board of AstraZeneca, GSK, Moderna, MSD, Novavax, Pfizer, and Sanofi. Manuel Baca Cots has collaborated in scientific training activities subsidized by GlaxoSmithKline, MSD, Pfizer, Sanofi, Seqirus, Novavax, and Moderna; as an investigator in clinical trials of vaccines from Almirall, AstraZeneca, GlaxoSmithKline, Medimmune, Merck, Moderna, MSD, Nestlé, Novavax, Novartis, Pfizer, Sanofi, Seqirus, and Wyeth; and as a consultant on the Advisory Board of GSK, MSD, Pfizer, and Sanofi. Javier Álvarez Aldeán has collaborated in teaching activities subsidized by AstraZeneca, GlaxoSmithKline, MSD, Pfizer, Sanofi, and Seqirus; as a researcher in clinical trials of GlaxoSmithKline and Sanofi; and as a consultant on the Advisory Board of AstraZeneca, GlaxoSmithKline, MSD, Pfizer, Sanofi, and Seqirus. María González López, Reyes Roldán López, Beatriz Relinque Macías, Sergio Ocaña Jaramillo, and Benito Amil Pérez declares no conflict of interest related to this work. Data availability statement The data that support the findings of this study are available from the corresponding author, Ignacio Salamanca de la Cueva, upon reasonable request. Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2686489 References Associated Data Supplementary Materials supplementary files.docx Data Availability Statement The data that support the findings of this study are available from the corresponding author, Ignacio Salamanca de la Cueva, upon reasonable request.